The number of people living with dementia globally more than doubled between 1990 and 2016 from 20.2 million to 43.8 million, prompting researchers to call for more preventative action.
A new paper published in The Lancet Neurology also found that 22.3 per cent of healthy years lost due to dementia in 2016 were due to modifiable risk factors.
Prepared by academics across multiple institutions and led by the University of Melbourne and the University of Washington, the paper looked at the global, regional and national burden of Alzheimer’s Disease and other dementias from 1990-2016.
The systematic analysis of the Global Burden of Disease Study 2016 found dementia was more common at older ages, with the prevalence doubling every five years over age 50. There was also significant potential for prevention.
"In our study, 22.3 per cent (11.8 - 35.1 per cent) of the total global disability-adjusted life years lost due to dementia in 2016 could be attributed to the four modifiable risk factors - being overweight, high blood sugar, consuming a lot of sugar sweetened beverages and smoking," the authors said.
University of Melbourne lead author Professor Cassandra Szoeke said even more risk factors would be explored in the new data collection.
"But already the importance of these risks in allowing us to prevent or delay dementia is clear," she said. "The paper noted that changes in risk factor exposure over time as we become healthier might account for several cohort studies documenting a reduction in age-specific incidence rates in their study populations."
Because dementia develops over at least 20 to 30 years before it is diagnosed, Professor Szoeke said studies needed to investigate cognition over 20 to 30 years to determine when and for how long intervention was needed to prevent disease.
She said most randomised controlled trials lasted one to five years and the necessary 30-year longitudinal studies were rare.
"In addition, when you look over decades there are so many exposures that impact on our health, you need to account for all these things or you could miss a factor that is crucial in the development of disease," she said.
Professor Szoeke said by 2050 the number of people living with dementia could be around 100 million. "The paper states that to support our community, we will need a larger workforce of trained health professionals as well as planning and building facilities and community-based services which support improved quality of life and function," she said.
"We need to enhance the quality of life and function of people living with cognitive impairment and focus on preventing further cognitive decline. This will need a co-developed community wide approach with well-developed services and an even greater network of trained health professionals.
"Chronic diseases are becoming the leading causes of death and disability worldwide, and whilst we continue to work daily on new therapies to target disease, at home we really need to focus more on the health choices that we know extend both disease-free and disability-free survival."
Professor Szoeke’s research is now available to all Australians through her Health Brain Initiative. Twitter: https://twitter.com/HBIstudy
Three of Australia’s child health leaders have joined forces to tackle global child health: The Murdoch Children’s Research Institute, the Royal Children’s Hospital and the University of Melbourne have launched a new initiative, Melbourne Children’s Global Health.
Former Victorian Premier John Brumby has officially opened the new ’Nancy Millis’ building, an expansion of the University of Melbourne Bio21 Institute of Molecular Science and Biotechnology , incorporating CSL’s Global Hub for Research and Translational Medicine.
Changing language in job advertisements and de-identifying CVs during recruitment can significantly boost a person’s prospects of landing a job by overcoming unconscious bias, new University of Melbourne research shows.
Epilepsy researchers from around the world have examined the DNA of more than 45 000 people, leading to the discovery of 11 genes associated with the disorder and pointing the way to drugs that might benefit millions of patients who do not respond to existing treatments.
Australian researchers have developed a tiny device that electrically stimulates the brain and could one day be used to treat conditions such as epilepsy and Parkinson’s disease without invasive surgery.